<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02079194</url>
  </required_header>
  <id_info>
    <org_study_id>SMC 2014-01-161</org_study_id>
    <nct_id>NCT02079194</nct_id>
  </id_info>
  <brief_title>Comparison Between P2Y12 Antagonist Monotherapy and Dual Antiplatelet Therapy After DES</brief_title>
  <acronym>SMART-CHOICE</acronym>
  <official_title>Comparison Between P2Y12 Antagonist MonotHerapy and Dual Antiplatelet Therapy in Patients UndergOing Implantation of Coronary Drug-Eluting Stents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy and safety of clopidogrel monotherapy versus aspirin plus P2Y12&#xD;
      antagonist following 3-month of DAPT in patients undergoing PCI with DES.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is a prospective, randomized, multi-center, open label, noninferiority trial.&#xD;
      Patients undergoing PCI with DES will be eligible. After successful PCI with DES, all&#xD;
      eligible patients will be randomized either to clopidogrel monotherapy or to aspirin plus&#xD;
      P2Y12 antagonist following 3-month of DAPT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">March 18, 2014</start_date>
  <completion_date type="Anticipated">July 7, 2020</completion_date>
  <primary_completion_date type="Actual">July 7, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A composite of death, myocardial infarction, or cerebrovascular events</measure>
    <time_frame>1 year</time_frame>
    <description>12 months after the index procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause Death</measure>
    <time_frame>1 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiac death</measure>
    <time_frame>1 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction (MI)</measure>
    <time_frame>1 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrovascular accident (CVA)</measure>
    <time_frame>1 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization (TLR)</measure>
    <time_frame>1 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization (TVR)</measure>
    <time_frame>1 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any revascularization</measure>
    <time_frame>1 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis: definite or probable stent thrombosis by ARC definition</measure>
    <time_frame>1 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BARC bleeding ≥2</measure>
    <time_frame>1 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BARC bleeding ≥3</measure>
    <time_frame>1 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiocerebral event (MACCE): death, MI, CVA, or any revascularization</measure>
    <time_frame>1 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3000</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>P2Y12 antagonist monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>P2Y12 antagonist monotherapy after 3-month DAPT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin + P2Y12 antagonist</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin + P2Y12 antagonist after 3-month DAPT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>P2Y12 antagonist monotherapy</intervention_name>
    <arm_group_label>P2Y12 antagonist monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin plus P2Y12 antagonist</intervention_name>
    <arm_group_label>Aspirin + P2Y12 antagonist</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject must be at least 20 years of age.&#xD;
&#xD;
          -  Subject is able to verbally confirm understandings of risks, benefits and treatment&#xD;
             alternatives and he/she or his/her legally authorized representative provides written&#xD;
             informed consent prior to any study related procedure.&#xD;
&#xD;
          -  Patients undergoing successful PCI&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hemodynamic instability or cardiogenic shock&#xD;
&#xD;
          -  Active bleeding&#xD;
&#xD;
          -  Known hypersensitivity or contraindication to study medications&#xD;
&#xD;
          -  Female of childbearing potential, unless a recent pregnancy test is negative, who&#xD;
             possibly plan to become pregnant any time after enrollment into this study&#xD;
&#xD;
          -  Non-cardiac co-morbid conditions are present with life expectancy &lt;2 year or that may&#xD;
             result in protocol non-compliance (per site investigator's medical judgment).&#xD;
&#xD;
          -  DES implantation within 12 months before index procedure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyeon-Cheol Gwon, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiac and Vascular Center; Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>March 3, 2014</study_first_submitted>
  <study_first_submitted_qc>March 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2014</study_first_posted>
  <last_update_submitted>January 29, 2019</last_update_submitted>
  <last_update_submitted_qc>January 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Hyeon-Cheol Gwon</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Drug-eluting stents</keyword>
  <keyword>aspirin</keyword>
  <keyword>P2Y12 antagonist monotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

